drugset / Trial / NCT07187466

Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease

NCT07187466

Phase 4 Not yet recruiting 146 enrolled VA Office of Research and Development
RandomizedSequentialSingle-blindTreatment

Summary

The purpose of this study is to learn about different treatments for overactive bladder symptoms in Parkinson's Disease. The investigators want to find out if people who do not respond to one treatment (either behavioral or drug treatment) will respond to combined treatment. The investigators also want to find out what factors influence whether someone responds to the treatments.

Timeline

Start
2026-07-01
Primary completion
2030-03-31
Completion
2030-06-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mirabegron Other / unclassified 25 mg